Drawing Patients Back to the Office During the Pandemic

Ophthalmology was the hardest hit healthcare specialty during the initial months of the coronavirus pandemic (March and April 2020), with an estimated 81% loss in practice volume. While many practices are seeing a revitalization of their patient numbers, the reality of the pandemic is that it’s not going away anytime soon. HCPs are instead having to implement changes to safety precautions, operating procedures, messaging to patients, and more, to ensure their client volume remains sustainable.

Building Trust in Your Practice

They key to bringing patients back through the door lies in the trust the client has in the practice. This means safety precautions are not just a means of protection against the virus; they serve to build confidence in your patients that your practice has their safety and best interests at heart.

Building this security comes from behaviors like the following:

  • Social distancing in seating areas
  • Requiring mask usage
  • Advanced sanitation protocols.

Communicating the Risk in Delaying Care

Clarifying the need to continue with ophthalmological surgeries and procedures is also a necessity for patients. For many, their reservations stem from weighing the risks and advantages of going through with surgery during the pandemic.

Waiting to follow through with a procedure until the coronavirus is fully resolved could mean waiting indefinitely, and the risks of holding off on certain procedures could be critical. For instance, postponing cross-linking for keratoconus could be more harmful if the condition continues to progress and the patient loses vision permanently.

Supporting Patients with Alternative Funding Options

For some patients, the coronavirus impacted their economic ability to access procedures and surgeries. To help with this, Glaukos offers a copay savings program to reduce out-of-pocket costs related to the FDA-approved iLink.

Through the iLink Copay Savings Program, patients with commercial insurance are eligible to get up to $100 toward their non-reimbursable copay expenses for iLink procedures. The company also offers a patient assistance program to support financially eligible, uninsured patients with drug costs at no charge.

For more about coronavirus recovery in practices, click here.

Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink™ corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]


Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epethelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.


1. Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016